Kornimate/medical-research-clean huggingface dataset:
the pain intensity of the patients who had undergone abdominal surgery with a midline incision

Conditions: Transcutaneous Electric Nerve Stimulation

Summary: the purpose of this study is to determine the effects of transcutaneous electrical nerve stimulation (tens) and transcutaneous acupoint electrical stimulation (taes) on pain and analgesic drug consumption in patients who had undergone abdominal surgery with a midline incision. evidence for the effects of and transcutaneous electrical stimulation on pain and analgesic consumption on patients undergoing abdominal surgery with severe pain experience and high levels of neuroendocrine stress response is uncertain.

this research was conducted as a randomized controlled trial. 158 patients who had undergone abdominal surgery with diagnosis of gastric and colorectal cancer were assessed for eligibility. this research sample consisted of 48 patients who underwent abdominal surgery with a midline incision. the patients were randomized into three groups, the first intervention group, which used tens (around the incision), the second intervention group, which used taes (st25, p6, st36, li̇4 acupuncture points) and the control group, which did not. electric stimulation was performed at the 30th minute, second, 18th, 21st, 40th, and 45th hours after the operation. pain scores and analgesic consumption were assessed in the first 48 hours after surgical intervention.

Eligibility criteria:
inclusion criteria: * patients who had an american society of anesthesiologists (asa) score of i-ii * patients were aged over 18 years * patients who could read and write turkish * patients who were scheduled to undergo elective abdominal surgery with a midline incision for a diagnosis of stomach or colorectal cancer * patients without any impairment of vision, hearing or speech exclusion criteria: * patients who had a pacemaker * patients whose skin integrity around the incision was degraded * patients had a cognitive disorder, had a history of chronic pain, or were suffering from neurological, renal, cardiac or pulmonary disorders that could affect the test results * patients with an opioid addiction * patients those who had previously undergone electrical stimulation treatment * morbidly obese subjects * patients using psychoactive drugs

Keywords: postoperative pain alternative therapy acupuncture tens surgical nursing randomised controlled trial
non-genetic risk factors of congenital cataracts

Conditions: Cataract

Summary: prevention and treatment of the reversible childhood blindness, including congenital cataracts (cc), has been listed as a significant component of the international programme "vision 2020 - the right to sight" launched by who in 1999. however, there is still a lot of unsolved problems regarding to cc, especially in developing countries, such as the delayed presentation and treatment to the hospitals, the lack of specialized treatment departments, and the poor treatment prognosis. with the two children policy opened in china in 2016, many cc parents hesitate to have a second child due to the potential high risk of cc. date on detailed clinical characteristics of the cc children, including the demography, pregnancy-labor history, and living condition, are crucial for developing the national screening strategies of cc in pregnant women. however, to our knowledge, it still lacks of thus large population-based and comprehensive investigations of the characteristics of cc children in developing countries.

prevention and treatment of the reversible childhood blindness, including congenital cataracts (cc), has been listed as a significant component of the international programme "vision 2020 - the right to sight" launched by who in 1999. however, there is still a lot of unsolved problems regarding to cc, especially in developing countries, such as the delayed presentation and treatment to the hospitals, the lack of specialized treatment departments, and the poor treatment prognosis. with the two children policy opened in china in 2016, many cc parents hesitate to have a second child due to the potential high risk of cc. date on detailed clinical characteristics of the cc children, including the demography, pregnancy-labor history, and living condition, are crucial for developing the national screening strategies of cc in pregnant women. however, to our knowledge, it still lacks of thus large population-based and comprehensive investigations of the characteristics of cc children in developing countries. supporting by the national ministry of health and the zhongshan ophthalmic center (zoc), a specialized eye facility with the largest cc database in china, we therefore comprehensively investigated the demography, pregnancy-labor history, and living condition of cc children with their first visits to the hospital. we also further established a mathematic model of non-genetic risk factors of congenital cataracts. the implications of this study will be of clinical importance to roughly predict the risk of cc in pregnant women.

Eligibility criteria:
inclusion criteria: * diagnosis of congenital cataract. * less than 18 years old. exclusion criteria: * the children with definite or suspected ocular trauma (including blunt trauma) history and those with regular ocular or systemic steroid history were excluded from this study. * the children came from the welfare homes with unclear family heredity and gestation history information were also excluded.

Keywords: congenital cataract risk factor mathematic model
a patient-centric, prospective, observational, non-interventional switch study of xywav in narcolepsy

Conditions: Narcolepsy

Summary: the rationale for the patient-centric, prospective, observational, non-interventional study design of jzp258-402 is to evaluate the transition experience of participants with narcolepsy treated with oxybate and to examine the impact of transitioning from xyrem to xywav in a real-world setting.


Eligibility criteria:
inclusion criteria: 1. male or female, aged 18 years or older 2. diagnosis of type 1 or type 2 narcolepsy by a physician 3. active prescription for xyrem with a stable treatment regimen for at least 2 consecutive months 4. transitioning from xyrem to xywav within the next or past 7 days (- 7 days or + 7 days from the first dose of xywav) 5. able to read and understand english 6. able to access to a computer/smart phone with internet connection 7. not currently a jazz pharmaceuticals employees or an immediate family member of a jazz employee 8. willing and able to comply with the study schedule 9. willing and able to provide electronically written informed consent
safety and efficacy of natalizumab in the treatment of crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderate to severely active crohn's disease. it is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. these cells are thought to cause damage in the bowel leading to the symptoms of crohn's disease.


Eligibility criteria:
male and female patients at least 18 years of age who have at least a six-month history of crohn's disease and who are currently experiencing moderate to severely active crohn's disease. women must not be breastfeeding or pregnant, and must not become pregnant during this study. patient enrollment requires previous participation in study an100226-cd301 (please refer to the clinical trial listing for cd301).
evaluation of the transend program

Conditions: Pediatric Patient Transfer to Adult Service:Transition Program

Summary: "transend" is a program designed to promote the transition of young patients with endocrine or metabolic diseases when they arrive in the adult sector at la pitié-salpétrière hospital. the main objective of the study is to compare the rate of patients lost to follow-up at 24 months after the transfer of pediatrics between the transend group and the (historical) control group.

adolescence and early adulthood represent important periods for young people suffering from chronic diseases. several observational studies show needs not covered by care services at this period and significant lost to follow-up rates. "transend" is a program designed to promote the transition of young patients with endocrine or metabolic diseases when they arrive in the adult sector at la pitié-salpétrière hospital (paris, france). since september 1, 2016, approximately 500 patients benefited from it.

Eligibility criteria:
inclusion criteria: * patient aged 18 to 32 * patient with endocrine or metabolic disease * patient who had a follow-up in a pediatric department for his endocrine or metabolic disease * patient transferred to the adult sector in the endocrinology, metabolism or nutrition department of pitié-salpêtrière * patient who had a first post-transfer consultation between january 1, 2015 and september 1, 2017 * patient with a social security protection exclusion criteria: * patient who transferred to another adult service before being followed at pitié-salpêtrière * patient who has expressed his opposition to participate in this research
obstructive apnea in patients submitted to partial laryngectomy

Conditions: OBSTRUCTIVE SLEEP APNEA

Summary: the investigators intend to study the prevalence of obstructive apnea in patients submitted to partial laryngectomy by larynx cancer. volunteers will be evaluated using polissonografy. we will try to correlate the residual glotic area with the number of apneas per hour.

we are trying to avaliate the residual glotic area using spirometry e laryngoscopy

Eligibility criteria:
inclusion criteria: * partial laringectomy, over 18 years, exclusion criteria: * tracheostomy depression use of drugs severe dpoc cancer recurrence

Keywords: obstructive sleep apnea laringectomy cpap
immunoregulatory effect of microparticle delivered sting agonist in the control of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms)

Conditions: Relapse Remitting Multiple Sclerosis

Summary: microparticles (mps) as a mode of therapeutic delivery can selectively deliver immunomodulatory treatment to the phagocytic cells, particularly dendritic cells (dcs), inducing their tolerogenic phenotype and function and t regulatory (treg) cell expansion. the study will characterize the in vitro response of cgamp immunomodulator incapsulated microparticles on the capacity of dcs and tregs to regulate the inflammatory response.

this is a lab study only. no medication will be dispensed as a part of the study. no tests or procedures will be performed. blood ( approximately 10 teaspoons ; 10 green top tubes) will be drawn by a qualified phlebotomist, nurse or physician in the neurology clinic, during routine clinic visits. proper medical procedures will be followed when collecting blood to minimize patient risk. in addition, steps will be taken to guard patient's confidentiality. unique codes will be assigned to each sample. all identifying information will be removed from samples and clinical data before they are given to the research staff conducting the laboratory study. only the clinic staff will have access to the consent forms, the master list (that connect the unique codes with the patient names) and subject medical records. the blood draw will coincide with the subject's regular visit to the neurology clinic. all records will be secured with the current pacs radiology system and computerized information systems/computerized databases which are the current methods for securing all patient information. care will be taken to preserve the confidentiality of all patient-related information. material with identifying information will be stored in the clinic locked data storage room. patient names will not be used in any publications. results of laboratory studies performed on these samples will not be shared with subjects. laboratory results will not be incorporated into patients medical records. the proposal states to separate dendritic cells using magnetic beads separation and use them as an antigen presenting cells to t cells.the therapeutic effect of the nanoparticle delivered phosphatidylserine (ps, par-ps) will be measured, using cytokine secretion and the detection of the t regulatory (treg) cell induction. proliferation will be determined using cfse, cytokine secretion will be measured using elisa and the intracellular cytokine staining for ifng, il-17a, il-17f, il-21, il-22, tgfb, il-10 and il-4. the induction of treg cells will be measured using flow cytometry and determining the percentage of cd4+ cd25+ cd127- foxp3+ treg cells within the cd4+ lymphocytes.

Eligibility criteria:
inclusion criteria: 1. subjects meeting diagnostic criteria for relapsing remitting multiple sclerosis 2. between the ages of 18-55 3. not treated with immunomodulatory therapy, no other neurological diagnosis, no other inflammatory disease exclusion criteria: -
an optimization in the postoperative treatment in head and neck--surgical patients.

Conditions: Hyperglycemia Steroid-induced; Hyperglycemia Stress; Surgery--Complications

Summary: based on glycemic load (overall increase in blood glucose), it is investigated whether better glycemic control (large fluctuations in blood glucose to abnormal values are attempted) can improve the postoperative phase of head and neck surgical patients who receive dexamethasone (glucocorticoid). furthermore it is examined whether this optimization in treatment can result in reduced hospitalization time and fewer re-admissions. hypothesis: continuous blood glucose measurement and insulin therapy will optimize the postoperative phase of the embedded head and neck patient receiving dexamethasone by reducing the incidence of hyperglycaemia and associated complications.

after surgical intervention, an insulin resistance condition will occur because of the following stress response. this condition will for the majority of cases results in poor glycemic control - and there will be a risk of hyperglycaemia in the hospitalized patient. this condition affects all cells in the body and therefore has associated complications such as bigger risk at multiple infections, longer healingprocess, poorer fluid balance, etc. hyperglycaemia is associated with a poorer outcome for the patient, which can cause an increase in hospitalization days and multiple re-admissions. it is also common for the postoperative patient to experience nausea and pain as a result of both surgery and anesthesia and immobilization. to counter this, the patient receives dexamethasone (steroid treatment). this experiment is based on the fact that there is still insufficient attention at this postoperative insulin resistance. in a large randomized study from 2001(van den berghe), insulin therapy was initiated for intensive patients. this study points out that even moderate increases in blood glucose are associated with increased morbidity and that insulin therapy is both capable of reducing mortality and morbidity.

Eligibility criteria:
inclusion criteria: * all embedded head and neck-surgical patients receiving large packs of pre-medication, including 8-16 mg glucocorticoid. * \>18 yrs. * expected admission time of a minimum of 1 day exclusion criteria: * patients who do not understand and / or speak danish * patients who are demented * patients included in primary robot surgery * ear-surgical patients * sinus surgery patients * day surgery patients * plastic surgical patients * patients who are scheduled to transfer to icu * patients with diabetes mellitus type i * patients on dialysis * if all preoperative blood samples and tests are not completed * type 2 diabetics in insulin therapy * anesthesia patients * patients who have received large packages of pre-medication twice - eg. due to cancelled operation.
rexulti drug general use-results survey (excessive motor activity or physically/verbally aggressive behavior due to rapid changes in mood, irritability, and/or outbursts associated with dementia due to alzheimer's disease)

Conditions: Alzheimer Disease

Summary: the purpose of this study is to evaluate safety of rexulti in patients under daily clinical settings. in addition, information on efficacy will be collected.


Eligibility criteria:
inclusion criteria: * patients diagnosed with alzheimer's disease exclusion criteria: -
effects of oral supplementation of arginine, zinc and vitamin c on collagen synthesis in inguinal hernia patients

Conditions: Inguinal Hernia

Summary: collagen synthesis is depressed systemically in the immediate postoperative period. arginine, zinc and vitamin c impact collagen synthesis. the aim of this study is to investigate the effect of a pre and postoperative oral supplement consisting of arginine, zinc and vitamin c on collagen synthesis in patients undergoing inguinal hernia repair.

the trial investigates the effect of a pre and postoperative oral supplement consisting of arginine, zinc and vitamin c on collagen type i synthesis in patients undergoing inguinal hernia repair. the patients in the intervention group are given 55 mg zinc, 1251 mg vitamin c, and 15 g arginine once daily 14 days pre-operatively and post-operatively. both groups receive high quality protein (1.5 g protein/kg body weight) daily during the same period. hernia repair is done using the lichtenstein technique. drainage tubes are placed in the wound during the surgery. epidermal wounds (10 mm) are made via the suction blister method on the ventral forearm of the patients on the day of surgery. blood samples are drawn at day -14, day 0, day 1 and day 2. the surgical drain is emptied and fluid collected at day 1 and day 2.the healing of the suction blisters is assessed by clinical criteria until healing.

Eligibility criteria:
inclusion criteria: * age above 18 years * patients undergoing hernia repair using the lichtenstein technique * written informed consent exclusion criteria: * former surgery in the same area within 5 years * dementia * dysregulated diabetes * systemic corticosteroid treatment * liver disease * kidney disease * cancer within 5 years * need of interpreter
a study of iron oligosaccharide in chf patients

Conditions: Heart Failure, Congestive

Summary: the purpose of this study is to determine the safety profile of iron oligosaccharide in patients with congestive heart failure with a need for parenteral iron.

iron dextrans have been marketed for more than 50 years and the compiled preclinical and clinical experience with iron dextrans in general is well established. pharmacosmos a/s already markets the iron dextran cosmofer® worldwide, except in the us where the product is named infed®. a new iron oligosaccharide has been manufactured by pharmacosmos a/s and it is a further development of cosmofer® where ferric hydroxide has been combined with low molecular weight oligosaccharides in a relatively strong complex. this iron carbohydrate complex builds on the well established efficacy and safety profile of existing iron dextran but with a significantly reduced anaphylactic potential. in order to ensure that iron oligosaccharide will not lead to unexpected adverse events the existing clinical information on iron dextrans in general needs to be supplied with clinical safety data from a limited number of relevant patients exposed to iron oligosaccharide in open label non-comparator studies. the primary objective of the present study is to obtain safety reassurance with the use of iron oligosaccharide given either as repeated iv boluses or as total dose infusion for the correction of anaemia in patients with congestive heart failure in order to ensure that iron oligosaccharide will not lead to unexpected adverse events in these patients.

Eligibility criteria:
inclusion criteria: * congestive heart failure * ≥ 18 years of age at screening * haemoglobin \< 110 g/l (or 6.8 mmol/l) * serum ferritin \< 800 µgram/l * life expectancy beyond 12 months * willingness to participate after written informed consent exclusion criteria: * non iron deficiency anaemia * iron overload or disturbances in utilisation of iron (e.g. haemochromatosis, haemosiderosis) * drug hypersensitivity (i.e. previous hypersensitivity to iron dextran or iron mono- or disaccharide complexes) * patients with a history of multiple allergies * decompensated liver cirrhosis and hepatitis (alanine aminotransferase \> 3 times normal) acute or chronic infections rheumatoid arthritis with symptoms or signs of active inflammation. pregnancy and nursing. to avoid pregnancy, women have to be postmenopausal, surgically sterile, sexually inactive or practice reliable contraception active bleeding planned elective surgery during the study where significant blood loss is expected participation in any other clinical trial within 3 months prior to screening

Keywords: congestive heart failure anaemia iron oligosaccharide
attenuation of tonal tinnitus by lateral inhibition therapy

Conditions: Tinnitus

Summary: lateral inhibition therapy (til) corrects the patient's hearing by notched amplification on the patient's listening soundtrack. this half-octave notch is targeted at tinnitus frequencies measured tonal. the device slightly increases the amplification around the notch, so that the cerebral cortex compensates for this "gap" in the sound spectrum, masking the crippling tinnitus at the same time. this research is based on a new algorithm developed by the siemens company which proposes an attenuation of tonal tinnitus by a til by notched amplification emitted by the hearing device, object of the study.

in france, up to 16 million people suffer from tinnitus or ringing in the ears daily. this parasitic sound that does not come from the patient's environment can interfere with each individual in a variable way, sometimes creating an insurmountable handicap which has not known any effective treatment validated to date. lateral inhibition therapy (til) corrects the patient's hearing by notched amplification on the patient's listening soundtrack. this half-octave notch is targeted at tinnitus frequencies measured tonal. the device slightly increases the amplification around the notch, so that the cerebral cortex compensates for this "gap" in the sound spectrum, masking the crippling tinnitus at the same time. this research is based on a new algorithm developed by the siemens company which proposes an attenuation of tonal tinnitus by a til by notched amplification emitted by the hearing device, object of the study.

Eligibility criteria:
inclusion criteria: * patient over 18 years old. * patient with disabling tonal tinnitus (thi score\> 40) for more than 6 months. * patient with a hearing loss of at least 25db, centered on the frequency of tinnitus and requiring hearing aids * patient who has never used a hearing aid or a tinnitus masking system. * patient who stopped all tinnitus treatment at least 1 month before the start of the study (drug treatment, psychotherapy). * patient being willing to attend all of the visits planned as part of the study. * patient affiliated or beneficiary of a social security scheme. * patient having signed the free and informed consent exclusion criteria: * minor patient. * patient with hyperacusis * patient already with a hearing aid or tinnitus masker. * patient undergoing psychotropic or neurotropic drug treatments. * patient with a history of psychological or psychiatric disorders. * patient with a contraindication to wearing hearing aids. * patient suffering from non-disabling tinnitus (thi score \<40). * patient suffering from intermittent, non-tonal or pulsatile tinnitus. * patient participating in another clinical study. * protected patients: adults under guardianship, curatorship or other legal protection, deprived of their liberty by judicial or administrative decision. * pregnant or breastfeeding woman